Hospital Santa Creu y Sant Pau
- Address
- lock Available on a paid plan
Hospital Santa Creu y Sant Pau - Neurodegenerative Disease Research
Hospital Santa Creu y Sant Pau is a leading medical research institution with specialized expertise in neurodegenerative disorders and cognitive health. The center demonstrates a strong commitment to advancing treatments for progressive neurological conditions through participation in innovative clinical trials focused on early-stage Alzheimer's Disease.
- Early Alzheimer's Disease intervention and progression studies
- Clinical dementia rating assessments and cognitive decline monitoring
- Novel therapeutic approaches for neurodegenerative conditions
The research center contributes to pivotal studies evaluating clinically meaningful disease progression in Alzheimer's patients, utilizing validated outcome measures such as the Clinical Dementia Rating (CDR) scale. Their involvement in cutting-edge therapeutic trials positions them at the forefront of developing disease-modifying treatments that may slow or halt cognitive deterioration in vulnerable patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Santa Creu y Sant Pau
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Remternetug (LY3372993) Versus Placebo in Early Alzheimer's Disease Patients at Risk for Cognitive and Functional Decline | Eli Lilly & Co. | Phase III | Not Recruiting | Apr 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| LY3372993 | 1 | Unknown | 2025-04-15 | 2025-04-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.